TL;DR
This study introduces a novel, combined approach using high-resolution mass spectrometry (HPLC-qTOFMS) and relative mass defect (RMD) analysis for rapid dereplication of phlorotannins from the brown alga Ecklonia cava. This method successfully identified known compounds and discovered two new phlorotannins, while also pinpointing phlorofucofuroeckol A as a promising antiviral agent against influenza A viruses.
What Problem Does This Paper Address?
Natural product research often involves the laborious process of isolating and identifying compounds from complex extracts. When dealing with organisms like brown algae, which are rich in structurally similar phlorotannins, this challenge is amplified. Researchers need efficient methods to quickly identify known compounds (dereplication) to avoid redundant work and to discover novel molecules. Furthermore, identifying bioactive compounds within these complex mixtures requires a way to link chemical profiles to biological activity. This paper addresses the need for a faster, more accurate, and bioactivity-guided method for phlorotannin dereplication and the identification of antiviral agents from Ecklonia cava.
Methods
The core of this research lies in the development and application of a dereplication strategy combining two key techniques:
- High-Performance Liquid Chromatography with Quadrupole-Time-of-Flight Mass Spectrometry (HPLC-qTOFMS): This technique separates compounds based on their retention time and then analyzes their mass-to-charge ratio with high accuracy. The MS/MS fragmentation patterns provide structural clues.
- Relative Mass Defect (RMD) analysis: This method leverages the deviation of a compound's exact mass from its nominal mass. Phlorotannins, with their high oxygen content, tend to have characteristic low RMD values, allowing for their classification and differentiation from other compound classes like fatty acids.
The study employed a bioactivity-guided isolation approach. First, an Ecklonia cava extract was fractionated, and fractions were screened for antiviral activity against the H1N1 influenza virus. The most active fraction (EC70) was then subjected to HPLC-qTOFMS and RMD analysis for dereplication. This allowed for the prediction of phlorotannin structures. Subsequently, these predicted compounds were isolated and their structures confirmed using NMR and further MS/MS analysis. Molecular modeling was used to determine the absolute configurations of the newly identified compounds. Finally, the antiviral activities of isolated phlorotannins were tested against H1N1 and H9N2 influenza strains.
Datasets
The study utilized an in-house database of phlorotannins from the Ecklonia genus, compiled from online databases and previous literature. This database, along with the generated HPLC-qTOFMS data from the Ecklonia cava extract, served as the basis for dereplication. No new public datasets were introduced.
Key Insights and Ideas
- RMD as a powerful phlorotannin fingerprint: The study highlights that phlorotannins exhibit characteristic low RMD values (typically < 200 ppm), making RMD analysis a highly effective tool for their initial identification and classification within complex mixtures.
- Synergy of HPLC-qTOFMS and RMD: Combining the separation power of HPLC, the high-resolution mass accuracy of qTOF-MS, and the structural information from RMD analysis provides a robust and rapid dereplication strategy.
- Bio-guided dereplication accelerates discovery: Integrating biological activity screening with analytical dereplication allows researchers to focus on identifying bioactive compounds, making the discovery process more efficient.
- Ecklonia cava as a rich source of antivirals: The research reinforces Ecklonia cava's potential as a source of natural compounds with significant antiviral properties, particularly against influenza viruses.
Key Results
- The EC70 fraction of Ecklonia cava extract showed the strongest antiviral activity against H1N1 influenza virus.
- Dereplication predicted thirteen phlorotannins in the EC70 fraction.
- Ten known phlorotannins were successfully isolated and identified.
- Two novel phlorotannins were discovered and their structures elucidated.
- Six of the seven tested phlorotannins exhibited moderate to strong antiviral activity against both H1N1 and H9N2 influenza A strains.
- Phlorofucofuroeckol A (compound 12) was identified as the most potent antiviral compound, with an EC50 value of 13.48 ± 1.93 μM against H1N1 virus. This compound demonstrated dose-dependent inhibition of viral protein synthesis, specifically neuraminidase and hemagglutinin.
Limitations and Future Work
- Database dependency: The accuracy of dereplication relies heavily on the comprehensiveness of the in-house and online databases. The discovery of new compounds is contingent on their novelty relative to existing entries.
- Structural elucidation complexity: While MS/MS and RMD provide strong evidence, definitive structural confirmation of novel compounds still requires extensive NMR analysis.
- In vitro to in vivo translation: The study demonstrates potent antiviral activity in cell-based assays. Further research is needed to evaluate the efficacy and safety of these compounds in animal models and ultimately in human clinical trials.
- Mechanism of action: While the study suggests inhibition of neuraminidase and hemagglutinin, a more detailed investigation into the precise molecular mechanisms of antiviral action for the identified compounds would be beneficial.
- Broader applications: The developed dereplication strategy could be applied to other marine natural products and complex plant extracts to accelerate the discovery of bioactive compounds.
Summary updated